vimarsana.com

Page 64 - புனே அடிப்படையிலானது சீரம் நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

State to buy one crore doses of vaccine

State to buy one crore doses of vaccine Updated: Updated: ₹483 crore needed for vaccine purchase, Cabinet against lockdown in State Share Article ₹483 crore needed for vaccine purchase, Cabinet against lockdown in State The State will purchase one-crore doses of COVID-19 vaccines directly from two manufacturers to make it available for those in the 18-45 age group. A Cabinet meeting chaired by Chief Minister Pinarayi Vijayan here on Wednesday took the decision hours before the online registration for those in the 18-45 age group began. The vaccines will cost the State ₹483 crore. Of the one-crore doses, 70 lakh doses will be Covishield from the Pune-based Serum Institute of India and the remaining Covaxin from the Hyderabad-based Bharat Biotech. The first 10-lakh doses will be purchased next week and the entire purchase will be completed by July.

Adar Poonawalla: Serum Institute of India CEO Adar Poonawalla to get Y category security

Synopsis Serum Institute of India s CEO Adar Poonawalla will get Y category security across India by the CRPF, the Union government officials said on Wednesday. The Union government s decision came after director, government and regulatory affairs at Pune-based Serum Institute of India (SII), Prakash Kumar Singh had written to Union home minister Amit Shah on April 16 requesting security for Poonawalla. Covishield maker, SII s Adar Poonawalla to get Y category security Serum Institute of India s CEO Adar Poonawalla will get Y category security across India by the CRPF, the Union government officials said on Wednesday. The Union government s decision came after director, government and regulatory affairs at Pune-based Serum Institute of India (SII), Prakash Kumar Singh had written to Union home minister Amit Shah on April 16 requesting security for Poonawalla.

Government s New Vaccine Strategy Is Bad Economics

Government s New Vaccine Strategy Is Bad Economics Government s New Vaccine Strategy Is Bad Economics Updated: April 27, 2021 9:36 am IST After a tightly centralized vaccination drive that has delivered the required two shots to less than 2% of the population, India is opening up its inoculation strategy in the middle of a raging pandemic. Can the new approach flatten the curve? Expanding the campaign to all adults below 45 starting next month is a late but welcome move. India s daily infection rate of almost 350,000 is the worst any country has experienced. Even then, shifting a big part of the financial burden to 28 state governments and letting private hospitals buy shots at 600 to 1200 rupees ($8 to $16) apiece - and sell them to patients at even higher prices - are both wrong.

india vaccination: View: India s new vaccine strategy is bad economics

Synopsis After the current spike has peaked, people will still need to be inoculated at a rapid pace to flatten the curve and avert a third buildup. And that’s when the folly of charging Rs 600 or Rs 1,200 for a life-saving vaccine, in a country where the working class was struggling to buy Rs 5 biscuits even before the pandemic, may become clear. A vaccine queue in Mumbai. The world’s biggest democracy can’t shut anyone out of the market for vaccines. After a tightly centralised vaccination drive that has delivered the required two shots to less than 2% of the population, India is opening up its inoculation strategy in the middle of a raging pandemic. Can the new approach flatten the curve?

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.